Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC
SAU:4017
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
55.4
64
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SAR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC
Cash Equivalents
Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC
SAU:4017
|
Cash Equivalents
ď·Ľ116.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dallah Healthcare Company SJSC
SAU:4004
|
Cash Equivalents
ď·Ľ10m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-15%
|
|
|
National Medical Care Company JSC
SAU:4005
|
Cash Equivalents
ď·Ľ0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mouwasat Medical Services Company SJSC
SAU:4002
|
Cash Equivalents
ď·Ľ91m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
A
|
Al Hammadi Holding Co
SAU:4007
|
Cash Equivalents
ď·Ľ350m
|
CAGR 3-Years
60%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
|
Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC
Glance View
In the bustling hub of healthcare innovation within the Kingdom of Saudi Arabia, Dr. Soliman Abdel Kader Fakeeh Hospital Company SCJSC stands out as a beacon of medical excellence and pioneering spirit. Founded to address the rising demand for quality healthcare services in the region, the company has grown from a single hospital into a comprehensive network of medical facilities. The core of its operations revolves around providing a full spectrum of healthcare services ranging from basic outpatient treatments to intricate surgical procedures and specialty care. The company integrates advanced medical technologies with a patient-focused care approach, ensuring that the population it serves receives both cutting-edge and compassionate treatment. Within its walls, dedicated teams of healthcare professionals work tirelessly to uphold a legacy of trust and expertise, attracting both local and international patients seeking superior medical attention. Financially, Dr. Soliman Abdel Kader Fakeeh Hospital Company operates through a multifaceted model that revolves around patient services, strategic partnerships, and insurance collaborations. By catering to a diverse array of medical needs, the company secures a steady revenue stream from its inpatient and outpatient services. Moreover, it has established alliances with various insurance companies, streamlining the payment processes for insured patients and enhancing financial access to healthcare services. Strategic expansions and the introduction of specialized units also contribute significantly to its revenue, allowing it to capture more market share and cater to niche medical needs. The organization's business acumen is evident in its ability to balance quality care with economic sustainability, ensuring its growth while maintaining high standards of healthcare delivery across the kingdom.
See Also
What is Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC's Cash Equivalents?
Cash Equivalents
116.5m
SAR
Based on the financial report for Dec 31, 2023, Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC's Cash Equivalents amounts to 116.5m SAR.
What is Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC's Cash Equivalents growth rate?
Cash Equivalents CAGR 1Y
-31%
Over the last year, the Cash Equivalents growth was -31%.
You don't have any saved screeners yet